691 results on '"Vittecoq, Olivier"'
Search Results
2. Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity
3. Bone, cognitive, and anthropometric profiles and their relation to fracture sites in fallers: a cross-sectional study
4. Arrêt du tabac, soins bucco-dentaires et devenir des rhumatismes inflammatoires
5. Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination
6. Épidémiologie de l’atteinte dermatologique dans le syndrome de Sjögren : données provenant de trois populations françaises de Syndrome de Sjogren primitif (TEARS, ASSESS, diapSS)
7. Impact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review.
8. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry.
9. Clinical impact of a personalized pharmaceutical plan on opioid management in non-cancer pain: a pilot study
10. Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort
11. Characterisation of airway disease associated with Sjögren disease
12. Effect of Lymphoma Treatment Approaches on Hematologic Response and Autoimmune Disease Activity in Sjögren's Patients with Lymphoma
13. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)
14. Microbiological diagnosis of suspected vertebral osteomyelitis with a focus on the yield of percutaneous needle biopsy: a 10-year cohort study
15. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials
16. Association Between the Number of Comorbidities and the Risk of a Serious Infection in Rheumatoid Arthritis Treated by a First Biologic Agent
17. Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
18. Predictors of treatment response in rheumatoid arthritis
19. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis
20. Facteurs prédictifs de réponses dans la polyarthrite rhumatoïde
21. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry
22. Conséquences du tabac sur le devenir de la polyarthrite rhumatoïde
23. Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab
24. Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
25. Ne négligeons pas les mesures non pharmacologiques de contrôle de la douleur et de correction de certains facteurs hygiéno-diététiques dans la prise en charge des rhumatismes inflammatoires chroniques
26. Approches non-pharmacologiques des rhumatismes inflammatoires chroniques. Une démarche holistique pour une prise en charge personnalisée
27. Lupus With Erosive Arthritis: A Singular Joint Phenotype of Lupus or Rhupus?
28. Rheumatoid arthritis, insulin resistance, and diabetes
29. Polyarthrite rhumatoïde, insulino-résistance et diabète
30. Le passage d’un anticorps anti-TNFα vers l’étanercept est plus bénéfique que l’inverse dans la polyarthrite rhumatoïde : étude rétrospective observationnelle sur 72 patients
31. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers
32. Impact des nouvelles recommandations du traitement médicamenteux de l’ostéoporose post-ménopausique. Étude rétrospective des patientes vues en consultation « ostéoporose » entre 2006 et 2012
33. Validation of the 2010-ACR/EULAR – classification criteria using newly EULAR-defined erosion for rheumatoid arthritis on the very early arthritis community-based (VErA) cohort
34. A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
35. Chapitre 58 - Arthrites inflammatoires
36. Validation des critères de classification ACR/EULAR 2010 – de la polyarthrite rhumatoïde en utilisant la nouvelle définition EULAR de l’érosion, dans la cohorte d’arthrites débutantes VErA
37. Biologic targeted therapies in pediatric rheumatology
38. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
39. Variability of Primary Sjögren's Syndrome Is Driven by Interferon α and Interferon α Blood Levels Are Associated With the Class II HLA–DQ Locus
40. Atteinte articulaire de la sarcoïdose et risque accru de survenue d’une spondyloarthrite. Étude cas-témoins monocentrique rétrospective
41. Clinical and ultrasonographic evaluation of the window of opportunity for retreatment with rituximab in rheumatoid arthritis patients from a multicentre real-life study
42. Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign
43. Efficacité des anti-TNF chez les patients atteints de spondyloarthropathie en l’absence de signes à l’imagerie
44. 08.02 Alpha-enolase promotes pro-inflammatory phenotype of monocytes-derived macrophages in vitro
45. Validation of FLARE‐RA, a Self‐Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare
46. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy – A pilot study from the VErA cohort
47. Évaluation de l’impact des recommandations de la Haute Autorité de santé sur la prise en charge thérapeutique de la polyarthrite rhumatoïde en pratique courante
48. L’expression synoviale de CD20 représente un nouveau facteur prédictif potentiel de la progression des érosions osseuses lors d’une arthrite très récente traitée par DMARD en monothérapie séquentielle – étude pilote à partir de la cohorte VErA
49. Main et poignet rhumatoïdes
50. Abatacept therapy and safety management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.